RBC Capital analyst Gregory Renza downgraded Morphic (MORF) to Sector Perform from Outperform with a price target of $57, down from $70. The firm views the Eli Lilly (LLY) takeover price as “fair and solid.” With limited antitrust concerns, RBC expects the deal to close in Q3 as guided.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF: